Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma
Summary: The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receivi...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223027074 |
| _version_ | 1827578679268474880 |
|---|---|
| author | Chen Jiang Li-Yun Huang Ji-Hao Zhou Zhi-Ming Li Yu Wang Shuo Li Jian-Chang Fu Qi-Tao Huang Qin Yan Yu-Yuan Huang Min Zuo Shimin Hu Robert Peter Gale Yang Liang Jing-Ping Yun Yu-Hua Huang |
| author_facet | Chen Jiang Li-Yun Huang Ji-Hao Zhou Zhi-Ming Li Yu Wang Shuo Li Jian-Chang Fu Qi-Tao Huang Qin Yan Yu-Yuan Huang Min Zuo Shimin Hu Robert Peter Gale Yang Liang Jing-Ping Yun Yu-Hua Huang |
| author_sort | Chen Jiang |
| collection | DOAJ |
| description | Summary: The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receiving ABVD therapy and demonstrated EBV-infection in their lymphoma cells with EBV-encoded small RNAs (EBERs) in situ hybridization. Subjects were divided into training and validation datasets. As data from the training dataset suggested EBERs-positivity was the only independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), we developed corresponding prognostic models based on it. Our models showed excellent performance in both training and validation cohort. These data indicate the close association of EBV infection and the outcomes of persons with NScHL receiving ABVD. Additionally, our newly developed models should help physicians estimate prognosis and select individualized therapy. |
| first_indexed | 2024-03-08T21:49:55Z |
| format | Article |
| id | doaj.art-44399e6c70214c8389f8b4b2c2964add |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-03-08T21:49:55Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-44399e6c70214c8389f8b4b2c2964add2023-12-20T07:35:27ZengElsevieriScience2589-00422024-01-01271108630Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphomaChen Jiang0Li-Yun Huang1Ji-Hao Zhou2Zhi-Ming Li3Yu Wang4Shuo Li5Jian-Chang Fu6Qi-Tao Huang7Qin Yan8Yu-Yuan Huang9Min Zuo10Shimin Hu11Robert Peter Gale12Yang Liang13Jing-Ping Yun14Yu-Hua Huang15State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaDepartment of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. ChinaDepartment of Pathology, Dongguan Children’s Hospital, Dongguan, Guangdong, P.R. ChinaDepartment of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, P.R. ChinaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACentre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UKState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding authorState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding authorState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding authorSummary: The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receiving ABVD therapy and demonstrated EBV-infection in their lymphoma cells with EBV-encoded small RNAs (EBERs) in situ hybridization. Subjects were divided into training and validation datasets. As data from the training dataset suggested EBERs-positivity was the only independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), we developed corresponding prognostic models based on it. Our models showed excellent performance in both training and validation cohort. These data indicate the close association of EBV infection and the outcomes of persons with NScHL receiving ABVD. Additionally, our newly developed models should help physicians estimate prognosis and select individualized therapy.http://www.sciencedirect.com/science/article/pii/S2589004223027074ImmunologyPublic healthCancer |
| spellingShingle | Chen Jiang Li-Yun Huang Ji-Hao Zhou Zhi-Ming Li Yu Wang Shuo Li Jian-Chang Fu Qi-Tao Huang Qin Yan Yu-Yuan Huang Min Zuo Shimin Hu Robert Peter Gale Yang Liang Jing-Ping Yun Yu-Hua Huang Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma iScience Immunology Public health Cancer |
| title | Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma |
| title_full | Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma |
| title_fullStr | Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma |
| title_full_unstemmed | Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma |
| title_short | Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma |
| title_sort | epstein barr virus based prognostic model in nodular sclerosis classic hodgkin lymphoma |
| topic | Immunology Public health Cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223027074 |
| work_keys_str_mv | AT chenjiang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT liyunhuang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT jihaozhou epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT zhimingli epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT yuwang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT shuoli epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT jianchangfu epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT qitaohuang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT qinyan epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT yuyuanhuang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT minzuo epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT shiminhu epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT robertpetergale epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT yangliang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT jingpingyun epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma AT yuhuahuang epsteinbarrvirusbasedprognosticmodelinnodularsclerosisclassichodgkinlymphoma |